Hematologic Oncology

A recent phase III study revealed a benefit with pacritinib for patients with myelofibrosis and thrombocytopenia who have experienced treatment failure with previous therapies.

Using CRISPR/Cas9 gene editing to remove CD7 from healthy T cells, researchers have found a way to use third party T cells for CAR-T therapy in T-cell hematologic malignancies.

Researchers have discovered that AML cells require high levels of cholesterol for survival, so the cholesterol pathway could represent a potential therapeutic option for the disease.

In this interview, Dr. Frederick Locke discusses the promise of CAR T-cell therapy for lymphomas, and how this gene therapy could offer hope for patients who don't respond to standard treatments.

Researchers report that PD-1/PD-L1 monoclonal blocking antibody allows T cells to remain active and fight malignant evolution, subsequently preventing tumor resistance.

Researchers examined more than 750 pedigrees of familial hematologic malignancies and found that the same genetic alteration may be responsible for Langerhans cell histiocytosis, acute myeloid leukemia, and primary idiopathic myelofibrosis.

FL progression risk at 2 years was twice as high in the high-risk vs the low-risk group, and the gene-expression score may help to guide treatment.

DLBCL patients who received in-hospital chemotherapy had a lower risk of death during hospitalization.

Nearly 80% of R/R myeloma patients with severe renal impairment requiring hemodialysis achieved disease control with this treatment combination.

The US FDA has granted Priority Review designation for tisagenlecleucel (Kymriah) for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for, or have relapsed after, ASCT.

A single infusion of the anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel produced durable remissions in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic lymphoma.

Pfizer’s rituximab investigational biosimilar PF-05280586 met the primary endpoint of overall response rate equivalence to rituximab-EU (MabThera) as a frontline treatment for patients diagnosed with CD20-positive follicular lymphoma, the company announced.

A new study demonstrates that it is possible to vaccinate patients with MDS against a decitabine-induced antigen and that the level of induced expression is sufficient to trigger cytotoxicity in patient-derived vaccine-induced T cells.

A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers.

PD-L1 expression was more common among patients with the GCB subtype of diffuse large B-cell lymphoma, and PD-L1 positivity predicted shorter survival.

BCR-ABL1 transcript levels at time points within the first year of therapy for CML can best predict the achievement of a deep molecular response.

Treatment with carfilzomib for multiple myeloma was associated with increased incidence of cardiovascular adverse events, especially with higher doses.

Continuous treatment with lenalidomide/dexamethasone significantly improved survival in patients with transplant-ineligible newly diagnosed multiple myeloma.

This video highlights research that found that single-cell RNA sequencing can better characterize patients and potentially improve multiple myeloma treatment in a more personalized manner.

This video highlights a study that establishes mutated CALR as a myeloproliferative neoplasms–specific tumor antigen and provides a rationale for the development of immunotherapies targeting mutated CALR.

Early disease progression for chronic lymphocytic leukemia was a robust prognostic factor for worse overall survival in patients treated with chemoimmunotherapy.

This video reviews classic syndromes associated with increased leukemia susceptibility and highlights pediatric patients who may be at increased risk for an inherited leukemia predisposition and should receive additional work-up.

Venetoclax has durable clinical activity in patients with relapsed/refractory chronic lymphocytic leukemia whose disease progressed during or after ibrutinib therapy.

This video highlights research into the use of post-transplant therapies to prevent or treat disease recurrence following allogeneic stem cell transplantation.

A combination of the FLT3 kinase inhibitor quizartinib with 5-azacitidine or low-dose cytarabine is active in patients with FLT3-ITD mutated myeloid leukemias, according to a new study.

CAR T cells targeting CD19 can be effective at treating relapsed/refractory diffuse large B-cell lymphoma or follicular lymphoma, with high rates of durable remission.

A new study has found that there are significant gaps in participation among people aged 75 and older in clinical trials of hematologic malignancies when considered against the incidence of these malignancies in this age group.

This video reviews updates on the treatment and biology of splenic and nodal marginal zone lymphoma.

History of Epstein-Barr virus or immunosuppression did not affect outcomes for patients with diffuse large B-cell lymphoma.

In this video reviews the management of nodular lymphocyte-predominant Hodgkin lymphoma.